Table 1 Basal characteristics of patients with PH divided by PH sub-group
From: Vitamin D deficiency among patients with pulmonary hypertension
PH subgroups | Total (n = 53) | Idiopathic (n = 16) | CTD (n = 9) | Congenital (n = 16) | HIV (n = 6) | Toxic (n = 1) | CTEPH (n = 5) | p value | |
|---|---|---|---|---|---|---|---|---|---|
Age (years; x ± SD) | 40.8 ± 16.5 | 38.5 ± 19.1 | 53 ± 14.9 | 33.2 ± 15.5 | 42.7 ± 6.4 | 47 | 45.4 ± 11.7 | 0.10 | |
Females (%) | 73.6 | 81.25 | 100 | 75 | 66.6 | 0 | 40 | 0.04 | |
FC (%) | I–II | 71.2 | 62.5 | 44.4 | 100 | 33.3 | 100 | 100 | 0.01 |
III–IV | 28.8 | 37.5 | 66.6 | 0 | 66.7 | 0 | 0 | 0.01 | |
Ht (%; x ± SD) | 43.9 ± 8.9 | 42.8 ± 5.7 | 40.3 ± 5.3 | 50.7 ± 11.4 * | 38.8 ± 9.1 | 42.1 | 42.1 ± 7.9 | 0.03 | |
Urea (mg/ml; x ± SD) | 34.49 ± 12.1 | 32.63 ± 9.6 | 32.50 ± 12.1 | 36.92 ± 17.1 | 33.33 ± 11.6 | 34 | 38 ± 5.2 | 0.91 | |
Creatinine (mg/dl; x ± SD) | 0.96 ± 0.9 | 0.76 ± 0.1 | 0.9 ± 0.1 | 1.29 ± 1.7 | 0.71 ± 0.1 | 1.4 | 0.98 ± 0.1 | 0.69 | |
Sodium (mEq/Lt; x ± SD) | 140.4 ± 2.6 | 139.7 ± 2.2 | 142.7 ± 2.2 | 140.4 ± 2.3 | 140.2 ± 2.8 | 141 | 138.8 ± 3.2 | 0.13 | |
Bilirubine (mg/dl; x ± SD) | 1.14 ± 1 | 1.14 ± 0.9 | 0.72 ± 0.1 | 1 ± 0.3 | 1.21 ± 1.3 | 1 | 2.08 ± 2.2 | 0.35 | |
6-min walk test ( x ± SD) | |||||||||
Distance (m) | 392.5 ± 132.2 | 395.8 ± 114 | 337.2 ± 136.7 | 440.5 ± 114.5 | 294.1 ± 160.7 | 557 | 430 ± 146.2 | 0.11 | |
Saturated O2, basal (%) | 94.5 ± 5.3 | 96.7 ± 3.3 | 95.1 ± 1.2 | 90.8 ± 7.9 * | 96.3 ± 1.3 | 98 | 95.25 ± 2.8 | 0.04 | |
Desaturation | −6.20 ± 6 | −5.33 ± 5.52 | −8.33 ± 3.93 | −9.07 ± 7.2 | −2.67 ± 4.76 | −1 | −2.75 ± 4.99 | 0.14 | |
Borg basal | 0.42 ± 0.86 | 0.57 ± 1.01 | 0.86 ± 1.18 | 0.17 ± 0.57 | 0.42 ± 0.80 | 0 | 0 | 0.50 | |
Borg final | 3.35 ± 2.36 | 3.57 ± 2.34 | 3.93 ± 3.14 | 2.50 ± 2.06 | 4 ± 2.36 | 3 | 3 ± 2.58 | 0.79 | |
Haemodynamic variables ( x ± SD) | |||||||||
SBP (mmHg) | 116.18 ± 17.76 | 110 ± 16.16 | 126.44 ± 18.37 | 114.45 ± 19.6 | 113.33 ± 17.51 | 135 | 117.5 ± 12.58 | 0.31 | |
DBP (mmHg) | 71.25 ± 10.59 | 71.23 ± 10.10 | 73.22 ± 15.03 | 67.73 ± 8.17 | 70 ± 8.94 | 85 | 75 ± 10 | 0.60 | |
HR (bts/min) | 81.9 ± 13 | 80.8 ± 15.1 | 83.4 ± 14.3 | 80 ± 11.4 | 88.2 ± 12.6 | 79 | 80.3 ± 13.5 | 0.89 | |
MPAP (mmHg) | 50.6 ± 17.7 | 55.7 ± 16.6 | 45.3 ± 6 | 56.7 ± 28.6 | 51.4 ± 7.7 | 29 | 38.8 ± 10.8 | 0.24 | |
PAWP (mmHg) | 10.9 ± 3.2 | 11 ± 2.7 | 9.8 ± 3.4 | 11.8 ± 4.7 | 12.2 ± 2.3 | 8 | 10 ± 2.5 | 0.63 | |
RAP (mmHg) | 8.6 ± 4.2 | 8.6 ± 4.5 | 8.1 ± 3.5 | 9.3 ± 3.2 | 10 ± 5.1 | 2 | 8.4 ± 5.7 | 0.66 | |
PVR (Wood units) | 8.71 ± 4.04 | 9.27 ± 2.34 | 8.88 ± 3.07 | 8.43 ± 7.05 | 10.44 ± 4.40 | 3.9 | 6.57 ± 3.48 | 0.56 | |
CI (bts/min/m2) | 2.73 ± 0.91 | 2.7 ± 0.69 | 2.12 ± 0.34 | 3.38 ± 1.33 | 2.4 ± 0.33 | 3.8 | 2.9 ± 1.13 | 0.07 | |
Treatment | |||||||||
Oral anticoagulation (n) | 24 | 8 | 6 | 3 | 2 | 1 | 4 | – | |
Calcium channel blockers (n) | 11 | 4 | 3 | 2 | 1 | 0 | 1 | – | |
PDE5 inhibitors (n) | 34 | 11 | 6 | 10 | 4 | 0 | 3 | – | |
Endothelin antagonists (n) | 11 | 4 | 1 | 5 | 1 | 0 | 0 | – | |
Prostanoids (n) | 3 | 3 | 0 | 0 | 0 | 0 | 0 | – | |